TEVA Teva Pharmaceutical Industries Ltd

  1. Stocks
  2. Healthcare
  3. NYSE: TEVA

Price (delayed)

$10.57

Market cap

$11.65B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.63

Enterprise value

$35.33B

Highlights
The debt has declined by 4.1% year-on-year and by 3.7% since the previous quarter
TEVA's gross margin is up by 2.2% YoY
Teva Pharmaceutical Industries's equity has decreased by 26% YoY
TEVA's quick ratio is down by 9% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com
Peers: PFE MRK

Key stats

What are the main financial stats of TEVA
Market
Shares outstanding
1.1B
Market cap
$11.65B
Enterprise value
$35.33B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.16
Price to sales (P/S)
0.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.17
Earnings
Revenue
$16.28B
EBIT
-$3.13B
EBITDA
-$1.6B
Free cash flow
-$100M
Per share
EPS
-$3.63
Free cash flow per share
-$0.09
Book value per share
$9.12
Revenue per share
$14.82
TBVPS
$18.43
Balance sheet
Total assets
$49B
Total liabilities
$38.03B
Debt
$25.43B
Equity
$10B
Working capital
$312M
Liquidity
Debt to equity
2.54
Current ratio
1.03
Quick ratio
0.52
Net debt/EBITDA
-14.84
Margins
EBITDA margin
-9.8%
Gross margin
46.3%
Net margin
-24.5%
Operating margin
-20.6%
Efficiency
Return on assets
-7.8%
Return on equity
-36.6%
Return on invested capital
-9.7%
Return on capital employed
-8.5%
Return on sales
-19.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TEVA stock price

How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
-2.58%
1 week
-1.49%
1 month
0%
1 year
-12.43%
YTD
9.53%
QTD
-8.41%

Financial performance

How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$16.28B
Gross profit
$7.54B
Operating income
-$3.36B
Net income
-$3.98B
Gross margin
46.3%
Net margin
-24.5%
TEVA's operating income is up by 7% from the previous quarter
TEVA's revenue is down by 4.7% year-on-year and by 2.3% since the previous quarter
The operating margin rose by 5% QoQ
The gross profit has declined by 2.6% year-on-year and by 2.4% since the previous quarter

Growth

What is Teva Pharmaceutical Industries's growth rate over time

Valuation

What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
1.16
P/S
0.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.17
Teva Pharmaceutical Industries's equity has decreased by 26% YoY
TEVA's price to book (P/B) is 5% higher than its last 4 quarters average of 1.1
TEVA's revenue is down by 4.7% year-on-year and by 2.3% since the previous quarter

Efficiency

How efficient is Teva Pharmaceutical Industries business performance
TEVA's ROE is down by 8% from the previous quarter
The company's return on invested capital rose by 4.9% QoQ
Teva Pharmaceutical Industries's return on sales has increased by 4% QoQ
Teva Pharmaceutical Industries's return on assets has decreased by 2.6% QoQ

Dividends

What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Teva Pharmaceutical Industries financials performed over time
The total assets is 29% greater than the total liabilities
The total assets is down by 11% year-on-year and by 3.2% since the previous quarter
TEVA's quick ratio is down by 9% YoY
The debt is 154% greater than the equity
TEVA's debt to equity is up by 30% YoY but it is down by 3.4% from the previous quarter
Teva Pharmaceutical Industries's equity has decreased by 26% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.